Compare · EYPT vs RVTY
EYPT vs RVTY
Side-by-side comparison of EyePoint Inc. (EYPT) and Revvity Inc. (RVTY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYPT and RVTY operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- RVTY is the larger of the two at $11.19B, about 11.7x EYPT ($960.0M).
- Over the past year, EYPT is up 28.5% and RVTY is up 8.0% - EYPT leads by 20.4 points.
- EYPT has been more active in the news (3 items in the past 4 weeks vs 2 for RVTY).
- RVTY has more recent analyst coverage (19 ratings vs 9 for EYPT).
- Company
- EyePoint Inc.
- Revvity Inc.
- Price
- $11.46-2.55%
- $100.33+1.92%
- Market cap
- $960.0M
- $11.19B
- 1M return
- -14.54%
- +1.48%
- 1Y return
- +28.48%
- +8.03%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 9
- 19
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest EYPT
- Chief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 3,627 shares, increasing direct ownership by 4% to 91,691 units (SEC Form 4) (withholding obligation)
- EyePoint Announces Participation at Upcoming Investor Conferences
- EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- EyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
- SEC Form 10-Q filed by EyePoint Inc.
- EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- EyePoint Reports First Quarter 2026 Financial Results and Highlights Recent Corporate Developments
- EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026
- SEC Form DEFA14A filed by EyePoint Inc.
Latest RVTY
- Wolfe Research resumed coverage on Revvity
- SEC Form SD filed by Revvity Inc.
- SEC Form 10-Q filed by Revvity Inc.
- Director Klobuchar Michael A was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Vandebroek Sophie V. was granted 2,280 shares, increasing direct ownership by 45% to 7,368 units (SEC Form 4)
- Director Michas Alexis P was granted 2,684 shares, increasing direct ownership by 4% to 63,767 units (SEC Form 4)
- Director Witney Frank was granted 2,280 shares, increasing direct ownership by 11% to 23,354 units (SEC Form 4)
- Director Witz Pascale was granted 2,280 shares, increasing direct ownership by 17% to 15,985 units (SEC Form 4)
- Director Barrett Peter was granted 2,280 shares, increasing direct ownership by 9% to 28,293 units (SEC Form 4)
- Director Mcmurry-Heath Michelle was granted 2,280 shares, increasing direct ownership by 54% to 6,513 units (SEC Form 4)